CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy
Table 3
CDK9 expression and breast cancer subtype/receptor status. This tables shows no significant association of CDK9 expression with breast cancer subtype and receptor status.
CDK9
Covariate
Statistics
Level
Negative N=31
Positive N=36
P-value
ER status
N (Col %)
Negative
14 (46.67)
9 (25)
0.066
N (Col %)
Positive
16 (53.33)
27 (75)
PR status
N (Col %)
Negative
17 (56.67)
12 (33.33)
0.057
N (Col %)
Positive
13 (43.33)
24 (66.67)
Her2Neu status
N (Col %)
Negative
23 (76.67)
30 (83.33)
0.498
N (Col %)
Positive
7 (23.33)
6 (16.67)
Subtype
N (Col %)
Triple negative
10 (34.48)
7 (19.44)
0.088
N (Col %)
ER+/PR+/Her2Neu-
9 (31.03)
21 (58.33)
N (Col %)
Other
10 (34.48)
8 (22.22)
Age at diagnosis (years)
N (Col %)
<50
11 (35.48)
14 (38.89)
0.774
N (Col %)
50+
20 (64.52)
22 (61.11)
Stage
N (Col %)
2
16 (53.33)
20 (57.14)
0.758
N (Col %)
3
14 (46.67)
15 (42.86)
The p-value is calculated by chi-square test or Fisher’s exact, where appropriate.
